The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Slamon, Professor and Chief of Hematology/Oncology, UCLA Department of Medicine, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's Cancer Research Program at Jonsson Comprehensive Cancer Center, discusses the implications from the phase III MONALEESA-3 trial for postmenopausal women with HR+ and HER2 negative advanced breast cancer
Tags: ESMO 2019
Published: 11 October 2019
Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma
Dr. Leslie, MD, Medical Oncologist, Regional Cancer Care Associates, offers her thoughts on the real-world evidence presented at ASH 2019 regarding CAR-T cell therapy in lymphoma
Dr. Leslie, MD, Medical Oncologist, Regional Cancer Care Associates, offers her thoughts on the real-world evidence presented at ASH 2019 ...
Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory ...
John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, elaborates on JAK inhibitors and combination therapies in the treatment of myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, elaborates on ...
Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, on whether molecular analysis is appropriate and helpful in determining treatment approaches for myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, on whether ...
Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers how physicians should be thinking about the use of BTK inhibitors ...
John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, tells us about his approach to the individualized management of myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, tells us ...
Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and other aggressive lymphomas
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and ...
Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, considers the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, considers ...
John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, shares outcomes from the MANIFEST study investigating CPI-0610 as a monotherapy or add-on to ruxolitinib in patients with myelofibrosis
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, shares outcomes ...
Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
Joshua Richter, MD, regarding the Phase 3 CANDOR study in relapsed/refractory multiple myeloma
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, tells us about the design and outcomes of the Phase 3 CANDOR study in relapsed/refractory multiple myeloma
John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, elaborates on JAK inhibitors and combination therapies in the treatment of myeloproliferative neoplasms
Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019
Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, offers his impression of the Phase 3 ICARIA-MM trial investigating isatuximab in relapsed/refractory multiple myeloma
Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory lymphoma
Joshua Richter, MD, provides opinion on the role of BCMA CAR-T cells in the management of MM
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, provides opinion on the role of BCMA CAR-T cells in the management of multiple myeloma (MM)
Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma
Dr. Leslie, MD, Medical Oncologist, Regional Cancer Care Associates, offers her thoughts on the real-world evidence presented at ASH 2019 regarding CAR-T cell therapy in lymphoma
Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML
Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, offers her overall impression on the changing FLT3 inhibition landscape in acute myeloid leukemia (AML)
Joshua Richter, MD, discusses the data investigating iberdomide presented at ASH 2019
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, discusses the data investigating iberdomide presented at ASH 2019
Leslie Popplewell, MD, on the role of CAR-T cell therapy in aggressive B-cell lymphomas
Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, shares her thoughts on the role of CAR-T cell therapy in the treatment of aggressive B-cell lymphomas
John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, shares outcomes from the MANIFEST study investigating CPI-0610 as a monotherapy or add-on to ruxolitinib in patients with myelofibrosis
Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia
Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, discusses the prognostic factors in acute myeloid leukemia (AML) and how these factors relate to outcomes for patients
Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, considers the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients
Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas
Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, summarizes the role of checkpoint inhibitors in the treatment of lymphomas as presented at ASH 2019
Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and other aggressive lymphomas
Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Madduri, Assistant Professor, Medicine, Hematology and Medical Oncology, The Mount Sinai Hospital, explains how JNJ-4528 differs from other CAR-T products
John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, tells us about his approach to the individualized management of myeloproliferative neoplasms
Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies
Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the STORM and Mammoth studies, investigating refractory multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care
Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma
Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in the treatment of myeloma
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.